Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 9
157
Views
11
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Two novel creatinine adducts of andrographolide in human urine

, , , &
Pages 911-916 | Received 20 Jan 2012, Accepted 26 Mar 2012, Published online: 09 May 2012
 

Abstract

  1. Andrographolide is a major labdane diterpenoid of the traditional Chinese and Ayurvedic medicine.

  2. Andrographis paniculate (Burm) Nees, is used in clinical situations in China mainly to treat fever, cold, and inflammation. In our previous study, fifteen metabolites of andrographolide were identified in human urine. However, there are still two other unknown metabolites. The aim of this study was to elucidate the structures of these two metabolites.

  3. 3. The two metabolites which are probably epimers were identified as creatinine adducts, and their structures were determined to be 14-deoxy-12-(creatinine-5-yl)-andrographolide-19-O-β-d-glucuronide A (Metabolite 1) and 14-deoxy-12-(creatinine-5-yl)-andrographolide-19-O-β-d-glucuronide B (Metabolite 2) by means of spectroscopic evidences.

  4. 4. It is for the first time that the formation of creatinine adducts as a novel metabolic pathway is reported. The mechanism was presumed that β-carbon (C-12) of α, β-unsaturated carbonyl was attacked by a 5-anion intermediate of creatinine formed through elimination of a proton, followed by the double bond migration from 12(13) to 13(14) and elimination of the hydroxyl group at C-14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.